Form 4: Pfizer EVP Granted 151,576 Stock Appreciation Rights

Pfizer Executive Vice President Michael McDermott was granted 151,576 stock appreciation rights with an exercise price of $26.58, vesting over five years.

Summary

• Michael McDermott, Executive Vice President of Pfizer Inc., was granted 151,576 Stock Appreciation Rights (SARs).
• The transaction date for this grant was March 3, 2026.
• The exercise price for these SARs is $26.58.
• The SARs are subject to certain vesting requirements and will be settled in shares of Pfizer common stock on the fifth anniversary of the grant date, which is March 3, 2031.
• Following this transaction, Michael McDermott beneficially owns 151,576 derivative securities (SARs) directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the alignment of executive incentives with shareholder value, which is a standard and generally beneficial corporate governance practice.

Positives

• The grant of Stock Appreciation Rights aligns the Executive Vice President's financial interests with the long-term performance of Pfizer's common stock.
• Equity-based compensation serves as an incentive for executive retention and performance.

Risks

• The value of the Stock Appreciation Rights is dependent on the future market price of Pfizer's common stock, which can fluctuate.
• The SARs are subject to vesting requirements, meaning the executive must meet certain conditions (e.g., continued employment) to fully realize their value.

Future Outlook

The Stock Appreciation Rights are designed to incentivize long-term performance, with vesting and settlement scheduled for March 3, 2031, linking the executive's future compensation to the company's stock performance over the next five years.

Management Comments

• The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.

Industry Context

StockSavvy.ai notes that equity-based compensation, such as Stock Appreciation Rights, is a prevalent practice in the pharmaceutical industry. This method is commonly used to align the interests of senior executives with those of shareholders, encouraging long-term value creation and executive retention within competitive talent markets.

Comparison to Industry Standards

• StockSavvy.ai observes that the grant of Stock Appreciation Rights to an Executive Vice President at a major pharmaceutical company like Pfizer is consistent with executive compensation strategies seen at industry peers such as Johnson & Johnson (JNJ) or Merck & Co. (MRK).
• These companies frequently utilize performance-based equity awards to incentivize leadership, linking executive rewards to stock price appreciation over multi-year vesting periods, thereby fostering long-term strategic alignment.

Related Party Transactions

• The grant of Stock Appreciation Rights to Executive Vice President Michael McDermott constitutes a related party transaction as it involves compensation from the company to a key executive.

Stakeholder Impact

• Shareholders: Potential positive impact through enhanced executive alignment with long-term stock performance.
• Management: Direct impact on the compensation and incentives for Executive Vice President Michael McDermott.

Next Steps

• Continued vesting of the Stock Appreciation Rights over the next five years.
• Settlement of the Stock Appreciation Rights in Pfizer common stock on March 3, 2031, subject to vesting conditions.

Key Dates

Recommendation

This Form 4 filing details a routine grant of stock appreciation rights to an executive, which is a standard component of executive compensation. It does not introduce new material information regarding Pfizer's operational performance, financial health, or strategic direction that would warrant a change in an existing investment recommendation. Therefore, a 'hold' recommendation is appropriate based solely on the content of this filing.

Keywords

Pfizer, PFE, Stock Appreciation Rights, SARs, Executive Compensation, Insider Transaction, Form 4, Michael McDermott, Equity Grant, Derivative Securities